Radiotherapy and anatomically defined pelvic second primary malignancies in 10-year rectal cancer survivors
Abstract
Second primary malignancy (SPM) associations after rectal cancer may depend on anatomical endpoint definitions. Using Surveillance, Epidemiology, and End Results data, we examined 24,551 patients who survived at least 10 years after surgery for rectal adenocarcinoma diagnosed during 2000–2012. First SPMs diagnosed at least 11 calendar years after the index year were analyzed using competing-risk methods with approximate year-based event times. Radiotherapy was not independently associated with all-site first SPMs. After correcting broad site categories, 277 events met a conservative anatomical pelvic definition excluding prostate cancer. Radiotherapy was associated with this endpoint (adjusted subdistribution hazard ratio 2.36, 95% confidence interval 1.48–3.75). At 10 years after the landmark, unadjusted cumulative incidence was 2.80% with recorded radiotherapy and 1.07% with no/unknown radiotherapy, a difference of 1.73 percentage points (95% confidence interval 1.22–2.25). Including prostate cancer attenuated the association (1.43, 0.99–2.07). These exploratory findings are definition-dependent associations among selected long-term survivors, not evidence of radiation-induced carcinogenesis or a basis for a new screening policy.
Related
- 454 Second primary hematologic malignancies in melanoma survivors before and after the introduction of immune checkpoint inhibitors: a population-based SEER analysis
- Second Primary Malignancies in Gastrointestinal Cancer Survivors: Epidemiology, Risk Factors, and Future Prediction Models
- Anatomically Defined Motor Phenotypes Reveal Dissociated Trajectories of Progression, Neurofilament Profiles, and Survival in ALS
- Association between the perivascular fat attenuation index and CCTA-defined anatomically significant left anterior descending coronary artery stenosis: relationship with serum inflammatory biomarkers
- Plasma Vitamin C, 25-Hydroxyvitamin D, and the Lactate-to-Albumin Ratio at PICU Admission in Survivors and Non-Survivors of Phoenix-Defined Pediatric Sepsis and Septic Shock: An Exploratory Prospective Cohort Study
BibTeX
@article{huang2026radiotherapy,
title = {{Radiotherapy and anatomically defined pelvic second primary malignancies in 10-year rectal cancer survivors}},
author = {Kanghua Huang},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-75612-y},
url = {https://www.nature.com/articles/s41598-026-75612-y},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Radiotherapy and anatomically defined pelvic second primary malignancies in 10-year rectal cancer survivors
AU - Kanghua Huang
PY - 2026
DA - 2026/10/14
JO - Scientific Reports
DO - 10.1038/s41598-026-75612-y
UR - https://www.nature.com/articles/s41598-026-75612-y
AB - Second primary malignancy (SPM) associations after rectal cancer may depend on anatomical endpoint definitions. Using Surveillance, Epidemiology, and End Results data, we examined 24,551 patients who survived at least 10 years after surgery for rectal adenocarcinoma diagnosed during 2000–2012. First SPMs diagnosed at least 11 calendar years after the index year were analyzed using competing-risk methods with approximate year-based event times. Radiotherapy was not independently associated with all-site first SPMs. After correcting broad site categories, 277 events met a conservative anatomical pelvic definition excluding prostate cancer. Radiotherapy was associated with this endpoint (adjusted subdistribution hazard ratio 2.36, 95% confidence interval 1.48–3.75). At 10 years after the landmark, unadjusted cumulative incidence was 2.80% with recorded radiotherapy and 1.07% with no/unknown radiotherapy, a difference of 1.73 percentage points (95% confidence interval 1.22–2.25). Including prostate cancer attenuated the association (1.43, 0.99–2.07). These exploratory findings are definition-dependent associations among selected long-term survivors, not evidence of radiation-induced carcinogenesis or a basis for a new screening policy.
SN - 2045-2322
ER -